Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib Food Effect and QTc Study
NCT05391022Phase 1Completed
- Sponsor
- Constellation Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of pelabresib in advanced cancer (2 arms), sponsored by Constellation Pharmaceuticals. Primary endpoints: Area under the concentration time curve at 21 days, Maximal plasma concentration at 21 days and 2 more. Started Jul 2021; status: completed.
02
Drugs
pelabresib
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT05391022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05391022.